Literature DB >> 11904666

A new prognostic scoring system for meningococcal septic shock in children. Comparison with three other scoring systems.

Alvaro Castellanos-Ortega1, Miguel Delgado-Rodríguez, Javier Llorca, Pilar Sánchez Burón, Santiago Mencía Bartolomé, Antonio Soult Rubio, Guillermo Milano Manso, Pedro Domínguez Sampedro, Ramiro Blanco Montero, Antonio Rodríguez Núñez, Elisa Zambrano Pérez, Corsino Rey Galán, Nuria López Negueruela, Roberto Reig Sáenz.   

Abstract

OBJECTIVE: To develop a quick and sensitive method for identification of children with presumed meningococcal septic shock at risk of death at admission to the pediatric intensive care unit (PICU) and to compare its performance with three other prognostic systems: Glasgow Meningococcal Septicaemia Prognostic Score (GMSPS), Malley score and the Paediatric Index of Mortality (PIM).
DESIGN: Multicenter retrospective cohort study.
SETTING: PICUs of 14 tertiary hospitals. PATIENTS: The developmental sample included 192 children consecutively admitted to the PICUs with presumed or confirmed meningococcal septic shock from 1983 to 1995. The validation sample included 158 children consecutively admitted from 1996 to 1998.
INTERVENTIONS: Clinical and laboratory data gathered during the first 2 h after admission were used to develop the new score and to compute the other scoring systems. Logistic regression was applied to identify the independent predictors of death. MEASUREMENTS AND
RESULTS: Overall mortality was 31.5%. The new score included seven variables: cyanosis (2 points), Glasgow coma scale less than 8 (2 points), refractory hypotension (2 points), oliguria (1 point), leukocytes less than 4000/mm(3) (1 point), partial thromboplastin time more than 150% of control value (1 point) and base deficit more than 10 mmol/l (1 point). The new score provided the best discriminative capability, as measured by the area under the ROC curve (SEM) in the validation sample =0.88 (0.03), PIM =0.82 (0.04), Malley I =0.80 (0.04), GMSPS =0.79 (0.04) and Malley II =0.76 (0.04).
CONCLUSIONS: A new prognostic score is proposed for therapeutic stratification of children with presumed meningococcal septic shock.

Entities:  

Mesh:

Year:  2002        PMID: 11904666     DOI: 10.1007/s00134-001-1196-z

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  5 in total

1.  A new prognostic scoring system for meningococcal septic shock in children: comparison with three other scoring systems.

Authors:  Nathan Kuppermann; Richard Malley; W Charles Huskins
Journal:  Intensive Care Med       Date:  2002-12-14       Impact factor: 17.440

2.  Changes in transfusion practice over time in the PICU.

Authors:  Michael D Dallman; Xinggang Liu; Anthony D Harris; John R Hess; Bennett B Edelman; David J Murphy; Giora Netzer
Journal:  Pediatr Crit Care Med       Date:  2013-11       Impact factor: 3.624

3.  Incidence of and mortality due to sepsis, severe sepsis and septic shock in Italian Pediatric Intensive Care Units: a prospective national survey.

Authors:  Andrea Wolfler; Paolo Silvani; Massimo Musicco; Massimo Antonelli; Ida Salvo
Journal:  Intensive Care Med       Date:  2008-05-24       Impact factor: 17.440

4.  A new scoring system derived from base excess and platelet count at presentation predicts mortality in paediatric meningococcal sepsis.

Authors:  Alexessander Couto-Alves; Victoria J Wright; Karnan Perumal; Alexander Binder; Enitan D Carrol; Marieke Emonts; Ronald de Groot; Jan Hazelzet; Taco Kuijpers; Simon Nadel; Werner Zenz; Padmanabhan Ramnarayan; Michael Levin; Lachlan Coin; David P Inwald
Journal:  Crit Care       Date:  2013-04-11       Impact factor: 9.097

5.  Can generic paediatric mortality scores calculated 4 hours after admission be used as inclusion criteria for clinical trials?

Authors:  Stéphane Leteurtre; Francis Leclerc; Jessica Wirth; Odile Noizet; Eric Magnenant; Ahmed Sadik; Catherine Fourier; Robin Cremer
Journal:  Crit Care       Date:  2004-05-21       Impact factor: 9.097

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.